NCT04172675 2026-02-24A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)Janssen Research & Development, LLCPhase 2 Completed107 enrolled 17 charts